Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × INDUSTRY × brolucizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

pembrolizumab 155 Paclitaxel 109 Carboplatin 107 Gemcitabine 100 Docetaxel 89 Cyclophosphamide 85 Nivolumab 75 Cisplatin 70 Rituximab 64 Bevacizumab 59 Dexamethasone 58 Capecitabine 54 Pemetrexed 49 fludarabine 48 Fluorouracil 44 atezolizumab 43 Azacitidine 43 venetoclax 41 Trastuzumab 36 Irinotecan 36 130-nm albumin-bound paclitaxel 34 Leucovorin 32 Cetuximab 32 Erlotinib Hydrochloride 30 Cytarabine 30 Fulvestrant 29 avelumab 27 Temozolomide 26 Prednisone 26 Oxaliplatin 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡